Stable and compact zwitterionic polydiacetylene micelles with tumor-targeting properties

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Stealth zwitterionic polydiacetylene-micelles are evaluated in vivo for the passive targeting of tumors.

Abstract

Compact polymerized polydiacetylene-micelles with “stealth” zwitterionic surface coating were assembled and tested in a murine xenograft model of breast cancer. In vivo fluorescence imaging indicated accumulation in the tumor area and histological studies revealed predominant uptake of the micelles at the margins of the tumor, thereby allowing the delineation of its volume.

Related collections

Most cited references 35

Record: found
Abstract: found
Article: not found

Applications of carbon nanotubes in drug delivery.

Alberto Bianco, Kostas Kostarelos, Maurizio Prato (2005)

The development of new and efficient drug delivery systems is of fundamental importance to improve the pharmacological profiles of many classes of therapeutic molecules. Many different types of drug delivery systems are currently available. Within the family of nanomaterials, carbon nanotubes (CNT) have emerged as a new alternative and efficient tool for transporting and translocating therapeutic molecules. CNT can be functionalised with bioactive peptides, proteins, nucleic acids and drugs, and used to deliver their cargos to cells and organs. Because functionalised CNT display low toxicity and are not immunogenic, such systems hold great potential in the field of nanobiotechnology and nanomedicine.

0 comments Cited 270 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.

Hiroshi Maeda (2012)

In this review, I have discussed various issues of the cancer drug targeting primarily related to the EPR (enhanced permeability and retention) effect, which utilized nanomedicine or macromolecular drugs. The content goes back to the development of the first polymer-protein conjugate anticancer agent SMANCS and development of the arterial infusion in Lipiodol formulation into the tumor feeding artery (hepatic artery for hepatoma). The brief account on the EPR effect and its definition, factors involved, heterogeneity, and various methods of augmentation of the EPR effect, which showed remarkably improved clinical outcomes are also discussed. Various obstacles involved in drug developments and commercialization are also discussed through my personal experience and recollections. Copyright © 2012 Elsevier B.V. All rights reserved.